Vijay  Shreedhar net worth and biography

Vijay Shreedhar Biography and Net Worth

Vijay joined Adamas as Chief Commercial Officer in May 2019 from Amgen Inc. where he served in a variety of sales and marketing roles of increasing responsibility in multiple therapeutic areas. Most recently, Vijay was Executive Director and Integrated Commercial Lead for the Multiple Myeloma franchise with responsibility for national sales, brand marketing, and regional marketing teams. He brings extensive US product launch experience, successfully leading the market entry of new entities, expanded indications for approved products, as well as new drug-delivery systems. He has led strategy and execution for multiple brands, including Neulasta®, XGEVA®, Vectibix®, and Kyprolis®, with a demonstrated track record of generating robust demand growth in highly competitive markets. Vijay started his professional career as a scientist in the field of Immuno-Oncology, earning his PhD at the University of Texas, M.D. Anderson Cancer Center and gaining experience in both academic and pharmaceutical research settings. He also earned an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania.

What is Vijay Shreedhar's net worth?

The estimated net worth of Vijay Shreedhar is at least $1.39 million as of March 22nd, 2021. Dr. Shreedhar owns 169,435 shares of Adamas Pharmaceuticals stock worth more than $1,392,756 as of April 23rd. This net worth estimate does not reflect any other investments that Dr. Shreedhar may own. Learn More about Vijay Shreedhar's net worth.

How do I contact Vijay Shreedhar?

The corporate mailing address for Dr. Shreedhar and other Adamas Pharmaceuticals executives is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. Adamas Pharmaceuticals can also be reached via phone at (510) 450-3500 and via email at [email protected]. Learn More on Vijay Shreedhar's contact information.

Has Vijay Shreedhar been buying or selling shares of Adamas Pharmaceuticals?

Vijay Shreedhar has not been actively trading shares of Adamas Pharmaceuticals within the last three months. Most recently, Vijay Shreedhar sold 6,200 shares of the business's stock in a transaction on Monday, June 21st. The shares were sold at an average price of $5.16, for a transaction totalling $31,992.00. Learn More on Vijay Shreedhar's trading history.

Who are Adamas Pharmaceuticals' active insiders?

Adamas Pharmaceuticals' insider roster includes Martha Demski (Director), Spyridon Papapetropoulos (Director), Christopher Prentiss (CFO), and Vijay Shreedhar (Insider). Learn More on Adamas Pharmaceuticals' active insiders.

Vijay Shreedhar Insider Trading History at Adamas Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2021Sell6,200$5.16$31,992.00View SEC Filing Icon  
3/22/2021Sell1,051$5.50$5,780.50169,435View SEC Filing Icon  
2/1/2021Sell4,514$6.39$28,844.46View SEC Filing Icon  
See Full Table

Vijay Shreedhar Buying and Selling Activity at Adamas Pharmaceuticals

This chart shows Vijay Shreedhar's buying and selling at Adamas Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adamas Pharmaceuticals Company Overview

Adamas Pharmaceuticals logo
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $8.22
Low: $8.22
High: $8.22

50 Day Range

MA: $8.17
Low: $7.97
High: $8.23

2 Week Range

Now: $8.22
Low: $4.02
High: $9.15

Volume

N/A

Average Volume

692,487 shs

Market Capitalization

$376.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82